David M. Thomas
A5057483557- Cancer Genomics and Diagnostics
- Sarcoma Diagnosis and Treatment
- Cancer-related Molecular Pathways
- BRCA gene mutations in cancer
- Genomics and Rare Diseases
- RNA modifications and cancer
- Bone Tumor Diagnosis and Treatments
- Epigenetics and DNA Methylation
- Genetic factors in colorectal cancer
- Lung Cancer Treatments and Mutations
- Cancer-related molecular mechanisms research
- Bone health and treatments
- Childhood Cancer Survivors' Quality of Life
- Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- Chromatin Remodeling and Cancer
- Ethics in Clinical Research
- Bioinformatics and Genomic Networks
- Cardiac tumors and thrombi
- Cancer Immunotherapy and Biomarkers
- Oral and Maxillofacial Pathology
- Molecular Biology Techniques and Applications
- Fibroblast Growth Factor Research
- Genomic variations and chromosomal abnormalities
- Musculoskeletal synovial abnormalities and treatments
UNSW Sydney
2015-2025
Garvan Institute of Medical Research
2015-2024
The Kinghorn Cancer Centre
2015-2024
St Vincent's Hospital Sydney
2019-2024
St Vincent's Clinic
2015-2024
Regional Medical Center
2024
Moffitt Cancer Center
1999-2023
St Vincent's Hospital
1995-2021
Oakland University
2013-2021
Office of Education
2020
Giant-cell tumor of bone (GCTB) is a locally aggressive, benign osteolytic in which destruction mediated by RANK ligand (RANKL). The RANKL inhibitor denosumab being investigated for treatment GCTB. We describe histologic analyses GCTB samples from phase II study GCTB.Adult patients with recurrent or unresectable received subcutaneous 120 mg every 4 weeks (with additional doses on days 8 and 15). primary efficacy endpoint was the proportion who had 90% more elimination giant cells their...
To evaluate the efficacy and safety of a slow-release formulation cytarabine (DepoCyt; Chiron Corp, Emeryville, CA, Skye Pharma, Inc, San Diego, CA) that maintains cytotoxic concentrations (ara-C) in CSF most patients for more than 14 days.Twenty-eight with lymphoma positive cytology were randomized to receive DepoCyt 50 mg once every 2 weeks or free ara-C twice week 1 month. Patients whose converted negative who did not have neurologic progression received an additional 3 months...
Patient stratification biomarkers that enable the translation of cancer genetic knowledge into clinical use are essential for successful and rapid development emerging targeted anticancer therapeutics. Here, we describe identification patient NVP-BGJ398, a novel selective fibroblast growth factor receptor (FGFR) inhibitor. By intersecting genome-wide gene expression genomic alteration data with cell line-sensitivity across an annotated collection lines called Cancer Cell Line Encyclopedia,...
Wnt signaling increases bone mass by stimulating osteoblast lineage commitment and expansion forms the basis for novel anabolic therapeutic strategies being developed osteoporosis. These include derepression of targeting secreted pathway antagonists, such as sclerostin. However, therapies are associated with safety concerns regarding an increased risk osteosarcoma, most common primary malignancy bone. Here, we analyzed 5 human osteosarcoma cell lines in a high-throughput screen...
Abstract BACKGROUND: Pigmented villonodular synovitis (PVNS) (also known as diffuse‐type giant cell tumor) and tenosynovial tumors (TGCT) are rare, usually benign neoplasms that affect the synovium tendon sheaths in young adults. These driven by overexpression of colony stimulating factor‐1 (CSF1). CSF1 is expressed a minority tumor cells, which, turn attract non‐neoplastic inflammatory cells express receptor (CSF1R) through paracrine effect. METHODS: Imatinib mesylate (IM) blocks CSF1R,...
Clinical specimens undergoing diagnostic molecular pathology testing are fixed in formalin due to the necessity for detailed morphological assessment. However, fixation can cause major issues with testing, as it causes DNA damage such fragmentation and non-reproducible sequencing artefacts after PCR amplification. In context of massively parallel (MPS), distinguishing true low frequency variants from remains challenging. The prevalence formalin-induced its impact on clinical genomics poorly...
Personalized medicine strategies using genomic profiling are particularly pertinent for pancreas cancer. The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) trial was initially designed to exploit results from genome sequencing of pancreatic cancer under the auspices International Genome Consortium (ICGC) in Australia. Sequencing revealed small subsets patients with aberrations their tumor that could be targeted currently available therapies.
<h3>Importance</h3> Osteosarcoma, the most common malignant bone tumor in children and adolescents, occurs a high number of cancer predisposition syndromes that are defined by highly penetrant germline mutations. The genetic susceptibility to osteosarcoma outside familial remains unclear. <h3>Objective</h3> To investigate architecture 1244 patients with osteosarcoma. <h3>Design, Setting, Participants</h3> Whole-exome sequencing (n = 1104) or targeted 140) DNA from 10 participating...
Fusion genes are a major cause of cancer. Their rapid and accurate diagnosis can inform clinical action, but current molecular diagnostic assays restricted in resolution throughput. Here, we show that targeted RNA sequencing (RNAseq) overcome these limitations. First, establish fusion gene detection with RNAseq is both sensitive quantitative by optimising laboratory bioinformatic variables using spike-in standards cell lines. Next, analyse patient cohort improve the overall rate from 63%...
Background Among sarcomas, which are rare cancers, many types exceedingly rare; however, a definition of ultra‐rare cancers has not been established. The problem sarcomas is particularly relevant because they represent unique diseases, and their rarity poses major challenges for diagnosis, understanding disease biology, generating clinical evidence to support new drug development, achieving formal authorization novel therapies. Methods Connective Tissue Oncology Society promoted consensus...
Abstract There are more than 70 distinct sarcomas, and this diversity complicates the development of precision-based therapeutics for these cancers. Prospective comprehensive genomic profiling could overcome challenge by providing insight into sarcomas’ molecular drivers. Through targeted panel sequencing 7494 sarcomas representing 44 histologies, we identify highly recurrent type-specific alterations that aid in diagnosis treatment decisions. Sequencing lead to refinement or reassignment...